All Drug Development articles – Page 24
-
ArticleThe future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted ...
-
ArticleWomen in Stem with Dr Amber D. Van Laar
Dr Amber Van Laar shares her remarkable journey in STEM. From a childhood fascination with science and medicine to a pivotal role as VP Clinical Development, AskBio. In this interview, she explores the profound impact of her early exposure to neuro-oncology, the challenges faced as a physician-scientist, and the pursuit ...
-
WebinarIon Channel Drug Discovery - Recent Advances in Novel Non-Opioid Pain Research
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
-
ArticleGamma delta T cells: a rising star in cancer therapy
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity ...
-
ReportBeyond the lab: artificial intelligence
Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.
-
NewsKey insights into vaccine development for herpesviruses
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
-
NewsCombatting HIV using gene therapy
Researchers have created a nanomedicine loaded with siRNAs, which demonstrated a 73 percent reduction in HIV replication.
-
NewsMitigating oxidative stress in neurodegenerative diseases
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.
-
ArticleWomen in Stem with Dr Beate Mueller-Tiemann
Introducing Dr Beate Mueller-Tiemann, whose journey spans continents and disciplines, with a passion for biochemistry and molecular biology since her high school days. From elucidating pivotal proteins in cancer to monoclonal antibody discovery, Dr Mueller-Tiemann's contributions have not only transformed our understanding of diseases but have also fuelled research in ...
-
ArticleInternational Day for Women and Girls in Science: Denise Bowser
The International Day for Women and Girls in Science: we have the privilege of engaging with Denise Bowser, a distinguished figure with a remarkable journey at Onyx Scientific. Join us as we explore Denise's experiences, the milestones and challenges she has encountered while navigating the dynamic ...
-
ArticleThe great prostate debate: innovations in prostate cancer screening
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its ...
-
ArticleWomen in Stem with Dr Sara Sangha
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Dr Sara Sangha, Associate Vice President of Medical Affairs and Head of US Medical Aesthetics at AbbVie. Over her almost 20 years with Allergan ...
-
ArticleThe promise of 3A5C7 mAb in the treatment of morphine tolerance
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia ...
-
ArticleWomen in Stem with Dr Mrunal Jaywant
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. We had the privilege of interviewing Dr Mrunal Jaywant, Vice President of R&D at USP India. At USP India, Dr Jaywant oversees the Compendial Development, the Synthetic Chemistry, ...
-
ArticleTransforming cancer treatment for greatest impact
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
-
ArticleGrowth hormone’s influence on neuropsychiatric disorders
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
-
ArticleThe science of ageing and restoring healthspan
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. Life Biosciences are specifically focused on restoring and prolonging one’s ...
-
ArticleAllosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
-
WebinarAdvancing therapeutics targeting cytokines with functional cell-based assays
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
-
NewsTargets for pancreatic cancer treatment found
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.